- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
Mosaic Clinical Technologies Announces FDA Breakthrough Device Designation for Cognita's Generative AI Model for Radiology
The AI model aims to improve radiological analysis and patient outcomes.
Mar. 5, 2026 at 7:38am
Got story updates? Submit your updates here. ›
Mosaic Clinical Technologies, a leading healthcare technology company, has announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation to Cognita's generative AI model for radiology. This designation is intended to expedite the development and review of innovative medical devices that have the potential to provide more effective treatment or diagnosis for life-threatening or irreversibly debilitating diseases or conditions.
Why it matters
The FDA's Breakthrough Device Designation is a significant milestone that recognizes the potential of Cognita's generative AI model to transform radiology and improve patient outcomes. This technology could lead to more accurate and efficient radiological analysis, ultimately enhancing the quality of healthcare delivery.
The details
Cognita's generative AI model for radiology utilizes advanced machine learning algorithms to analyze medical images and provide clinicians with insights that can aid in diagnosis and treatment planning. The Breakthrough Device Designation will allow Mosaic Clinical Technologies to work closely with the FDA to expedite the development and review process, ensuring that this innovative technology can reach patients as quickly as possible.
- On March 5, 2026, Mosaic Clinical Technologies announced that the FDA has granted Breakthrough Device Designation to Cognita's generative AI model for radiology.
The players
Mosaic Clinical Technologies
A leading healthcare technology company that develops innovative solutions to improve patient outcomes.
Cognita
A company that specializes in developing advanced generative AI models for various industries, including healthcare.
U.S. Food and Drug Administration (FDA)
The federal agency responsible for regulating and supervising the safety and effectiveness of medical devices in the United States.
What’s next
With the Breakthrough Device Designation, Mosaic Clinical Technologies and Cognita will work closely with the FDA to expedite the development and review process for the generative AI model, with the goal of bringing this innovative technology to market as soon as possible.
The takeaway
The FDA's Breakthrough Device Designation for Cognita's generative AI model for radiology is a significant step forward in the integration of advanced AI technologies into healthcare, with the potential to improve radiological analysis and ultimately enhance patient outcomes.
